Cargando…
Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study
PURPOSE: Age induces a progressive decline in functional reserve and impacts cancer treatments. Telomere attrition leads to tissue senescence. We tested the hypothesis that telomere length (TL) could predict patient vulnerability and outcome with cancer treatment. PATIENTS AND METHODS: An ancillary...
Autores principales: | Falandry, Claire, Horard, Béatrice, Bruyas, Amandine, Legouffe, Eric, Cretin, Jacques, Meunier, Jérôme, Alexandre, Jérôme, Delecroix, Valérie, Fabbro, Michel, Certain, Marie-Noëlle, Maraval-Gaget, Raymonde, Pujade-Lauraine, Eric, Gilson, Eric, Freyer, Gilles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712332/ https://www.ncbi.nlm.nih.gov/pubmed/26638179 |
Ejemplares similares
-
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
por: Tuefferd, Marianne, et al.
Publicado: (2007) -
Predicting tumor response and outcome of second-look surgery with (18)F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer
por: Aide, Nicolas, et al.
Publicado: (2020) -
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
por: Ray-Coquard, I, et al.
Publicado: (2013) -
Optimal management of breast cancer in the elderly patient: current perspectives
por: Le Saux, Olivia, et al.
Publicado: (2015) -
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
por: Ray-Coquard, I, et al.
Publicado: (2009)